

1.Kim WS, Buske C, Ogura M et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017; epub ahead of print
2.Jurczak W, Moriera I, Kanakasetty GB ert al. Rituximab biosimilar and reference rituximab in patients with previously untreated advnaced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol 2017; epub ahead of print